169 related articles for article (PubMed ID: 10945321)
1. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient.
Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic drug monitoring of immunosuppresants].
Hashida T; Inui K
Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126
[TBL] [Abstract][Full Text] [Related]
3. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
Goto M; Masuda S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
Pharmacogenetics; 2002 Aug; 12(6):451-7. PubMed ID: 12172213
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients.
Masuda S; Uemoto S; Goto M; Fujimoto Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2004 Apr; 75(4):352-61. PubMed ID: 15060513
[TBL] [Abstract][Full Text] [Related]
5. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.
Masuda S; Goto M; Okuda M; Ogura Y; Oike F; Kiuchi T; Tanaka K; Inui K
Transplant Proc; 2005 May; 37(4):1728-9. PubMed ID: 15919446
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation.
Masuda S; Goto M; Kiuchi T; Uemoto S; Kodawara T; Saito H; Tanaka K; Inui K
Liver Transpl; 2003 Oct; 9(10):1108-13. PubMed ID: 14526408
[TBL] [Abstract][Full Text] [Related]
7. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients.
Hosohata K; Masuda S; Yonezawa A; Katsura T; Oike F; Ogura Y; Takada Y; Egawa H; Uemoto S; Inui K
Pharm Res; 2009 Jul; 26(7):1590-5. PubMed ID: 19267185
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
[TBL] [Abstract][Full Text] [Related]
9. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation.
Hashida T; Masuda S; Uemoto S; Saito H; Tanaka K; Inui K
Clin Pharmacol Ther; 2001 May; 69(5):308-16. PubMed ID: 11371998
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
12. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients.
Masuda S; Goto M; Fukatsu S; Uesugi M; Ogura Y; Oike F; Kiuchi T; Takada Y; Tanaka K; Inui K
Clin Pharmacol Ther; 2006 Jan; 79(1):90-102. PubMed ID: 16413244
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
[TBL] [Abstract][Full Text] [Related]
15. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
16. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
[TBL] [Abstract][Full Text] [Related]
17. The expression of intestinal CYP3A4 in the piglet model.
Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y
Transplant Proc; 2004 Mar; 36(2):361-3. PubMed ID: 15050159
[TBL] [Abstract][Full Text] [Related]
18. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
19. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
von Ahsen N; Richter M; Grupp C; Ringe B; Oellerich M; Armstrong VW
Clin Chem; 2001 Jun; 47(6):1048-52. PubMed ID: 11375290
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole.
Zhao W; Fakhoury M; Maisin A; Baudouin V; Storme T; Deschênes G; Jacqz-Aigrain E
Ther Drug Monit; 2012 Dec; 34(6):739-41. PubMed ID: 23042259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
